Salarius stockholders approve reverse stock split and Nasdaq 20% share issuance

Decoy Therapeutics Inc.

Reverse stock split approved at ratio of 1:4 to 1:40; Board retains discretion on timing and exact ratio.
Nasdaq 20% issuance proposal passed, authorizing shares under December 2024 purchase agreement with C/M Capital Master Fund, LP.
Adjournment proposal passed but was not needed; quorum of 37.10% (789,213 of 2,127,286 shares) was present.
Reverse split vote: 561,364 for, 224,901 against; issuance vote: 124,631 for, 73,764 against (589,723 broker non-votes).

item 5.07

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.